RecruitingNCT06855329

PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

Studying Idiopathic pulmonary fibrosis

Last synced from ClinicalTrials.gov May 11, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Massachusetts, Worcester
Principal Investigator: Fernando J Martinez, MD, MS
University of Massachusetts, Worcester
Enrollment: 500 target
Eligibility: 18-80 years · All sexes
Timeline: 2025 – 2029

Study locations (13)

University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
University of Michigan, Ann Arbor, Michigan, United States
University of Texas Southwestern, Dallas, Texas, United States
University of Virginia, Charlottesville, Virginia, United States
University of Washington, Seattle, Washington, United States
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Prince Charles Hospital, Brisbane, Queensland, Australia
Austin Health, Melbourne, Victoria, Australia
University of Calgary, Calgary, Alberta, Canada
University of British Columbia, Vancouver, British Columbia, Canada
University College Dublin, Dublin, Ireland, Ireland
Royal Brompton, London, Greater London, United Kingdom
University Hospital Southampton, Southampton, Hampshire, United Kingdom

Collaborators

University of Michigan · University of Virginia · Johannes Gutenberg University Mainz · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06855329 on ClinicalTrials.gov

Other trials for Idiopathic pulmonary fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic pulmonary fibrosis →

← Back to all trials